Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.79 |
| ▸ | WNT1 | P04628 | 15/20 | 0.79 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.69 |
| ▸ | CLK2 | P49760 | 5/20 | 0.69 |
| ▸ | CLK3 | P49761 | 4/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17565812 | 0.92 | WNT1 (0.81) | TGFBR1WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17565859 | 0.92 | WNT1 (0.84) | TGFBR1WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17574845 | 0.90 | CLK2 (0.74) | TGFBR1WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17566009 | 0.90 | WNT1 (0.73) | TGFBR1WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17566661 | 0.90 | WNT1 (0.83) | TGFBR1WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17565795 | 0.89 | WNT1 (0.81) | TGFBR1WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17565902 | 0.89 | WNT1 (0.79) | TGFBR1WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17566658 | 0.89 | WNT1 (0.80) | TGFBR1WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17566042 | 0.88 | WNT1 (0.79) | TGFBR1WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17566027 | 0.88 | WNT1 (0.74) | TGFBR1WNT1DYRK1ACLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119276-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2019-04-25 | — | — | US | claimed |
| US-10202377-B2 | 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-12 | — | — | US | claimed |
| US-20180086754-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-03-29 | — | — | US | claimed |
| US-9657016-B2 | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-05-23 | — | — | US | claimed |
| WO-2016040180-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2016-03-17 | — | — | WO | claimed |
| US-20190119276-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2019-04-25 | — | — | US | disclosed |
| US-10202377-B2 | 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180086754-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-03-29 | — | — | US | disclosed |
| US-20180086754-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-03-29 | — | — | US | disclosed |
| US-9657016-B2 | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657016-B2 | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160068529-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068529-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068529-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | TGFBR1 625/4885WNT1 1/4885DYRK1A 1074/4885 |
| US-20180086754-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | TGFBR1 625/4885WNT1 1/4885DYRK1A 1074/4885 |
| US-10202377-B2 | 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | TGFBR1 625/4885WNT1 1/4885DYRK1A 1074/4885 |
| US-20190119276-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | TGFBR1 625/4885WNT1 1/4885DYRK1A 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.